Sign In
Buy PEN
$319.37
+0.630 (+0.198%)
At Close: Jun 03, 2026
Despite Seeing Accelerated 2023 Growth, This Analyst Cut Penumbra's Price Target - Here's Why
04:05pm, Wednesday, 04'th May 2022
Penumbra Inc (NYSE: PEN) reported Q1 sales that beat Street expectations, driven by Vascular upside, and reiterated its 2022 revenue guidance. Wells Fargo lowered the price target to $265 from
Penumbra's (PEN) CEO Adam Elsesser on Q1 2022 Results - Earnings Call Transcript
11:32pm, Tuesday, 03'rd May 2022
Penumbra, Inc. (NYSE:PEN ) Q1 2022 Earnings Conference Call May 3, 2022 4:30 PM ET Company Participants Jee Hamlyn-Harris – Investor Relations Adam Elsesser – Chairman and Chief Executive Officer
Penumbra, Inc. Schedules First Quarter 2022 Earnings Release and Conference Call for May 3, 2022
04:05pm, Tuesday, 05'th Apr 2022
ALAMEDA, Calif. , April 5, 2022 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN) today announced that it will host a conference call to discuss financial results for the first quarter 2022 after market clos
Penumbra, Inc. to Present at the 21st Annual Needham Virtual Healthcare Conference
04:05pm, Monday, 28'th Mar 2022
ALAMEDA, Calif. , March 28, 2022 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN) today announced that its management team is scheduled to present at the 21st Annual Needham Virtual Healthcare Conference on
These 3 Stocks Aren't Large Caps Yet, but They Each Could Make $1 Billion in Sales in 2022
04:00pm, Friday, 25'th Mar 2022
Looking for small healthcare companies with huge revenue opportunities? Try these.
Down 16% In A Month, Will Penumbra Stock Rebound?
06:30am, Tuesday, 15'th Mar 2022
The stock price of Penumbra, a medical devices company focused on interventional therapies, has seen a 16% fall in a month, while it was down 10% last week. The company reported mixed Q4 results last
Penumbra Stock: A Medical Device Recovery Play With Strong Growth Potential
06:33pm, Sunday, 06'th Mar 2022 Seeking Alpha
Penumbra A Little Beaten Down Despite Strong Growth Opportunities
09:48pm, Tuesday, 01'st Mar 2022 Seeking AlphaPenumbra A Little Beaten Down Despite Strong Growth Opportunities
04:48pm, Tuesday, 01'st Mar 2022
Penumbra has been posting strong revenue growth numbers, but the Street has not been rewarding the shares.
Penumbra Posts Mixed Bag Q4 Results, Reports Topline Growth Of 22%
02:05pm, Wednesday, 23'rd Feb 2022
Penumbra Inc (NYSE: PEN) posted Q4 FY21 revenue of $204 million, +22.2% Y/Y (up 23% in constant currency), beating the consensus of $194.30 million. Revenue from sales of vascular products grew 30.4
Wall Street Analysts Believe Penumbra (PEN) Could Rally 40%: Here's is How to Trade
11:34am, Wednesday, 23'rd Feb 2022
The average of price targets set by Wall Street analysts indicates a potential upside of 40.2% in Penumbra (PEN). While the effectiveness of this highly sought-after metric is questionable, the positi
Penumbra, Inc. (PEN) CEO Adam Elsesser on Q4 2021 Results - Earnings Call Transcript
02:33am, Wednesday, 23'rd Feb 2022 Seeking AlphaPenumbra, Inc. (PEN) CEO Adam Elsesser on Q4 2021 Results - Earnings Call Transcript
09:33pm, Tuesday, 22'nd Feb 2022
Penumbra, Inc. (PEN) CEO Adam Elsesser on Q4 2021 Results - Earnings Call Transcript
Penumbra GAAP EPS of -$0.66 misses by $0.30, revenue of $204M beats by $9.71M
09:12pm, Tuesday, 22'nd Feb 2022 Seeking Alpha
Penumbra press release (PEN): Q4 GAAP EPS of -$0.66 misses by $0.30.Revenue of $204M (+22.2% Y/Y) beats by $9.71M.
Penumbra, Inc. Reports Fourth Quarter and Full Year 2021 Financial Results
09:05pm, Tuesday, 22'nd Feb 2022 PR Newswire
ALAMEDA, Calif., Feb. 22, 2022 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN), a global healthcare company focused on innovative therapies, today reported financial results for the fourth quarter and full year ended December 31, 2021. Financial Highlights: Revenue of $204.0 million for the
